癌研連線CancerLink
Not yet recruiting NCT07570667

Global Longitudinal Health Monitoring and Blood Sample Collection Study to Promote Early-stage Disease Detection and Personalized/Precision Care Using Innovative Research Platforms

Lung CancerN/AStage IStage II

The investigators propose a prospective, longitudinal, observational study to improve health assessment by analyzing blood plasma molecular patterns in each individual over time using artificial intelligence (AI) to identify key measurements for early detection of NCDs. It will develop personalized reference ranges and screening methods, laying the foundation for population-based early detection. This study focus on collecting health data and biospecimen samples to understand early molecular changes linked to disease.

Conditions: CVD, Type 2 Diabetes, COPD, Cancer, Hypertension

Eligibility Criteria

Inclusion Criteria

  • Signed informed consent form (ICF) of the study.
  • Male or female participants.
  • Age at Visit 1: 40 years - 70 years.
  • For Low-risk Arm: Has low risk to contract an NCD in the upcoming years, according to the following criteria: a) Non-hypertensive person according to criteria of the relevant national guideline, who never received antihypertensive medication; b) Total cholesterol: \< 5.2 mmol/L (\<200 mg/dL) with no history of lipid-lowering (e.g., statin) treatment; c) Non smoker or with no significant smoking history (\<5 pack-years); For High-risk Arm: Has high risk to contract an NCD in the upcoming years, confirmed by the presence of at least 2 out of the following 3 criteria (a, b, c): a) Medically controlled hypertension: participants with diagnosed hypertension receiving antihypertensive medication ; b) Medically controlled dyslipidemia or hypercholesterolemia: participants with diagnosed dyslipidemia or hypercholesterolemia receiving lipid-lowering medication; c) Significant smoking history (tobacco exposure of \>20 pack-years) and/or 1st degree family member with history of lung cancer.
  • BMI: 18.5 - 35.0 kg/m\^2.
  • Willingness to fill in the study questionnaire.
  • Willingness to participate in future visits and medical investigations as defined per protocol.
  • Willingness to be followed-up on disease outcome through data linkage to the participant's health-related records.
  • History of HIV, HBV, HCV or HEV infection at Visit 1.
  • Vulnerable participants.
  • Foreseeable lack of compliance.

Exclusion Criteria

  • Pregnancy at Visit 1 (self-reported, no test required).

Eligibility criteria are kept as the original English records from ClinicalTrials.gov; actual eligibility is determined by the research team's formal assessment and the informed consent form. Source: ClinicalTrials.gov, updated automatically every two weeks. Last synced: 2026年10月8日.